Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus
about
Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication.Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions presentEffect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection.Antiviral treatment of chronic hepatitis B virus (HBV) infectionsThe HBV drug entecavir - effects on HIV-1 replication and resistanceStudy on the antiviral activity of San Huang Yi Gan Capsule against hepatitis B virus with seropharmacological method.Safety and efficacy of entecavir for the treatment of chronic hepatitis B.Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection.Changes in Mitochondrial Toxicity in Peripheral Blood Mononuclear Cells During Four-Year Administration of Entecavir Monotherapy in Chinese Patients with Chronic Hepatitis BManagement of patients with HBeAg-negative chronic hepatitis BThe anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patientsUpdate on entecavir in the management of severe forms of Hepatitis B.Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.Inhibition of hepatitis B virus polymerase by entecavir.Synthesis of cyclopentanyl carbocyclic 5-fluorocytosine ((-)-5-fluorocarbodine) using a facially selective hydrogenation approach.Pharmacokinetic properties of a novel inosine analog, 4'-cyano-2'-deoxyinosine, after oral administration in rats.
P2860
Q28366818-BF4B72F3-B83B-4C71-963D-4E25DCF7CC09Q33267067-CE07C68E-1775-44DF-A8EA-D503836D9F16Q33755065-5405ABFE-1AC4-47F9-968C-21276AB95A98Q34223779-FFB3EA5F-7A54-42DF-A9A1-85212AA04B00Q34639926-B040AA1B-BF14-4797-B3C1-A9319CD8DFD5Q35001215-FA3C1184-558B-4B65-BAF3-D2B61A9EBF4BQ35026611-FA16162F-36BE-4C32-901A-5B79042A0F60Q35166065-10B88CBC-C4A1-40B5-A29E-D89FC5166501Q35891653-CEDB43DF-5747-48BD-9ABF-D5D20E04D081Q36724421-D3B2E77A-B1EE-478A-AE2C-746CA24B5A7DQ37293650-200360F4-36BE-4A68-9F1F-7311FA4BAA61Q38201711-091B52AF-4CB8-4E8B-8875-5FC9CF171A59Q39652624-44735032-D503-43B0-A645-8E2E797D7441Q40176633-B3638459-DB12-4748-8374-872CC5111109Q41770273-DA534B71-720C-4A5C-B095-1D9C1208951CQ55237382-8DC30F7E-0B7F-4A4B-9BE0-4616259A25F7
P2860
Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Metabolic studies on BMS-20047 ...... tive against hepatitis B virus
@ast
Metabolic studies on BMS-20047 ...... tive against hepatitis B virus
@en
Metabolic studies on BMS-20047 ...... tive against hepatitis B virus
@nl
type
label
Metabolic studies on BMS-20047 ...... tive against hepatitis B virus
@ast
Metabolic studies on BMS-20047 ...... tive against hepatitis B virus
@en
Metabolic studies on BMS-20047 ...... tive against hepatitis B virus
@nl
prefLabel
Metabolic studies on BMS-20047 ...... tive against hepatitis B virus
@ast
Metabolic studies on BMS-20047 ...... tive against hepatitis B virus
@en
Metabolic studies on BMS-20047 ...... tive against hepatitis B virus
@nl
P2093
P2860
P356
P1476
Metabolic studies on BMS-20047 ...... tive against hepatitis B virus
@en
P2093
Bisacchi GS
Colonno RJ
Rinehart JK
Yamanaka G
P2860
P304
P356
10.1128/AAC.43.1.190
P407
P577
1999-01-01T00:00:00Z